5 Stocks Pushing The Health Care Sector Downward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 10 points (-0.1%) at 15,618 as of Friday, Aug. 2, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 1,354 issues advancing vs. 1,554 declining with 118 unchanged.

The Health Care sector currently sits up 0.2% versus the S&P 500, which is down 0.1%. On the negative front, top decliners within the sector include Sirona Dental Systems ( SIRO), down 5.3%, Regeneron Pharmaceuticals ( REGN), down 2.3%, Vertex Pharmaceuticals ( VRTX), down 2.0%, Celgene Corporation ( CELG), down 2.0% and Baxter International ( BAX), down 1.9%. Top gainers within the sector include Biogen Idec ( BIIB), up 2.8%, Smith & Nephew ( SNN), up 2.6%, Grifols ( GRFS), up 1.3% and Pfizer ( PFE), up 0.6%.

TheStreet would like to highlight 5 stocks pushing the sector lower today:

5. CareFusion ( CFN) is one of the companies pushing the Health Care sector lower today. As of noon trading, CareFusion is down $2.96 (-7.6%) to $35.99 on heavy volume. Thus far, 7.6 million shares of CareFusion exchanged hands as compared to its average daily volume of 2.1 million shares. The stock has ranged in price between $35.06-$39.14 after having opened the day at $39.14 as compared to the previous trading day's close of $38.95.

CareFusion Corporation provides various healthcare products and services in the United States and internationally. It operates in two segments, Medical Systems and Procedural Solutions. CareFusion has a market cap of $8.5 billion and is part of the health services industry. Shares are up 35.0% year to date as of the close of trading on Thursday. Currently there are 6 analysts that rate CareFusion a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates CareFusion as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, compelling growth in net income, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full CareFusion Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

4. As of noon trading, Illumina ( ILMN) is down $1.45 (-1.8%) to $78.00 on average volume. Thus far, 568,218 shares of Illumina exchanged hands as compared to its average daily volume of 1.3 million shares. The stock has ranged in price between $77.56-$80.00 after having opened the day at $79.94 as compared to the previous trading day's close of $79.45.

Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation and biological function in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. Illumina has a market cap of $10.0 billion and is part of the drugs industry. Shares are up 43.6% year to date as of the close of trading on Thursday. Currently there are 8 analysts that rate Illumina a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Illumina as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, impressive record of earnings per share growth, compelling growth in net income, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Illumina Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, Questcor Pharmaceuticals ( QCOR) is down $4.00 (-5.7%) to $66.05 on heavy volume. Thus far, 2.3 million shares of Questcor Pharmaceuticals exchanged hands as compared to its average daily volume of 2.1 million shares. The stock has ranged in price between $65.35-$70.55 after having opened the day at $68.92 as compared to the previous trading day's close of $70.05.

Questcor Pharmaceuticals, Inc., a biopharmaceutical company, provides drugs for the treatment of multiple sclerosis, nephrotic syndrome, and infantile spasms indications. It primarily offers H.P. Questcor Pharmaceuticals has a market cap of $4.0 billion and is part of the drugs industry. Shares are up 149.5% year to date as of the close of trading on Thursday. Currently there are 6 analysts that rate Questcor Pharmaceuticals a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Questcor Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, increase in stock price during the past year and growth in earnings per share. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Questcor Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Medtronic ( MDT) is down $0.94 (-1.7%) to $54.55 on heavy volume. Thus far, 6.0 million shares of Medtronic exchanged hands as compared to its average daily volume of 5.1 million shares. The stock has ranged in price between $54.35-$55.16 after having opened the day at $54.91 as compared to the previous trading day's close of $55.49.

Medtronic, Inc. manufactures and sells device-based medical therapies worldwide. The company operates in two segments, Cardiac and Vascular Group, and Restorative Therapies Group. Medtronic has a market cap of $55.7 billion and is part of the health services industry. Shares are up 34.7% year to date as of the close of trading on Thursday. Currently there are 7 analysts that rate Medtronic a buy, no analysts rate it a sell, and 12 rate it a hold.

TheStreet Ratings rates Medtronic as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, growth in earnings per share, attractive valuation levels and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Medtronic Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Express Scripts ( ESRX) is down $0.53 (-0.8%) to $65.03 on average volume. Thus far, 2.3 million shares of Express Scripts exchanged hands as compared to its average daily volume of 4.4 million shares. The stock has ranged in price between $64.86-$65.74 after having opened the day at $65.51 as compared to the previous trading day's close of $65.56.

Express Scripts Holding Company provides a range of pharmacy benefit management (PBM) services primarily in the United States and Canada. It offers healthcare management and administration services on behalf of its clients. Express Scripts has a market cap of $53.7 billion and is part of the health services industry. Shares are up 21.4% year to date as of the close of trading on Thursday. Currently there are 13 analysts that rate Express Scripts a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Express Scripts as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, compelling growth in net income, good cash flow from operations, largely solid financial position with reasonable debt levels by most measures and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Express Scripts Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 4 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

null

More from Markets

Video: You Could Live in a Ritz-Carlton or St. Regis Home

Video: You Could Live in a Ritz-Carlton or St. Regis Home

Stocks Trade Mixed, Energy Shares Fall on Sharp Drop in Oil Prices

Stocks Trade Mixed, Energy Shares Fall on Sharp Drop in Oil Prices

Component Stocks Rise After Trump Reverses Decision on ZTE

Component Stocks Rise After Trump Reverses Decision on ZTE

Crude Slides as Russia Eases Cuts and U.S. Oil Producers Boost Rig Count

Crude Slides as Russia Eases Cuts and U.S. Oil Producers Boost Rig Count

Best Buy's Billionaire Founder: We Were 'Late to the Game' in Online Shopping

Best Buy's Billionaire Founder: We Were 'Late to the Game' in Online Shopping